非小细胞肺癌新辅助免疫治疗后患者术后辅助治疗模式的生存分析及预后生物标志物探索
非小细胞肺癌新辅助免疫治疗后术后辅助治疗模式的生存分析与预后生物标志物探索:一项真实世界多中心回顾性研究
The aim of this observational study is to investigate the survival differences among patients with non-small cell lung cancer who received different adjuvant treatments after neoadjuvant immunotherapy, and to identify the main clinical characteristics of these survival differences. The main question it aims to answer is:
- Is there a difference in survival between patients who achieve pCR after neoadjuvant immunotherapy and those who do not receive adjuvant therapy?
- What are the recurrence patterns and high-risk factors for recurrence in patients with pCR after neoadjuvant immunotherapy, and how can early intervention be carried out?
- Is there a difference in survival among patients with non-MPR after neoadjuvant immunotherapy when they receive different adjuvant treatment modalities (single immunotherapy, chemio-immunotherapy, chemotherapy, etc.)?
- Should patients with non-MPR after neoadjuvant immunotherapy continue immunotherapy, and what are the predictive markers for receiving adjuvant therapy?
研究概览
地位
条件
详细说明
The aim of this observational study is to investigate the survival differences among patients with non-small cell lung cancer who received different adjuvant treatments after neoadjuvant immunotherapy, and to identify the main clinical characteristics of these survival differences. The main question it aims to answer is:
- Is there a difference in survival between patients who achieve pCR after neoadjuvant immunotherapy and those who do not receive adjuvant therapy?
- What are the recurrence patterns and high-risk factors for recurrence in patients with pCR after neoadjuvant immunotherapy, and how can early intervention be carried out?
- Is there a difference in survival among patients with non-MPR after neoadjuvant immunotherapy when they receive different adjuvant treatment modalities (single immunotherapy, chemio-immunotherapy, chemotherapy, etc.)?
- Should patients with non-MPR after neoadjuvant immunotherapy continue immunotherapy, and what are the predictive markers for receiving adjuvant therapy? Participants will undergo neoadjuvant immunotherapy and surgical procedures, and through rigorous analysis of real-world data, this study endeavors to provide nuanced insights into these fundamental queries, fostering advancements in clinical decision-making and patient management strategies.
研究类型
注册 (估计的)
联系人和位置
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100020
- Cancer Hospital, Chinese Academy of Medical Sciences
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients with lung cancer who have received neoadjuvant immunotherapy and surgery.
描述
Inclusion Criteria:
- Patients who visited the hospital from January 2020 to December 2023;
- Received neoadjuvant immunotherapy before surgery;
- Histologically diagnosed with stage II-III NSCLC;
- Had measurable lesions as assessed by the investigator using the RECIST 1.1 version;
- Underwent radical surgical treatment;
- ECOG score of 0 or 1;
- Available tumor tissue samples;
- Good blood and organ functions.
Exclusion Criteria:
- Has received other anti-tumor treatments before, including radiotherapy, chemotherapy and traditional Chinese medicine-based cancer treatment (except for malignant tumor treatments that have been cured and have no recurrence or metastasis for more than 5 years);
- Has a history of previous malignant tumors.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:OTHER
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS)
大体时间:From date of diagnosis until the date of death from any cause, whichever came first, assessed up to 7 years and 11 months.
|
OS is defined as the time from surgery time until death from any cause. |
From date of diagnosis until the date of death from any cause, whichever came first, assessed up to 7 years and 11 months.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Event-free survival(EFS)
大体时间:up to 7 years and 11 months.
|
Event-free survival was defined as the time from neoadjuvant treatment to metastasis or death by any cause in the absence of metastasis. |
up to 7 years and 11 months.
|
|
Pathological Complete Response(pCR)
大体时间:up to 1 month after surgery
|
After evaluating the removed tumor tissue and the regional lymph nodes, no residual tumor cells were found. |
up to 1 month after surgery
|
合作者和调查者
调查人员
- 首席研究员:Shugeng Gao, MD、Cancer Institute and Hospital, Chinese Academy of Medical Sciences
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.